Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$287,490.

  • SAB Biotherapeutics' Change in Accured Expenses fell 115.49% to -$287,490 in Q3 2025 from the same period last year, while for Sep 2025 it was -$103,750, marking a year-over-year decrease of 106.44%. This contributed to the annual value of -$1.2 million for FY2024, which is 28.21% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Change in Accured Expenses is -$287,490, which was down 127.62% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Change in Accured Expenses ranged from a high of $3.0 million in Q1 2021 and a low of -$2.0 million during Q2 2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$287,490 (2025), whereas its average is -$146,308.
  • In the last 5 years, SAB Biotherapeutics' Change in Accured Expenses skyrocketed by 22,512.85% in 2021 and then tumbled by 265.24% in 2023.
  • SAB Biotherapeutics' Change in Accured Expenses (Quarterly) stood at $276,329 in 2021, then slumped by 215.89% to -$320,231 in 2022, then soared by 538.06% to $1.4 million in 2023, then tumbled by 202.66% to -$1.4 million in 2024, then slumped by 115.49% to -$287,490 in 2025.
  • Its Change in Accured Expenses stands at -$287,490 for Q3 2025, versus $1.0 million for Q2 2025 and $583,073 for Q1 2025.